Interestingly, neither subgroup differed in demographic parameters, age, the WHO functional class, NTproBNP level, functional echocardiographic parameters, PAH treatment method, including parenteral prostacyclin, comorbidities, mental status, or quality of life. This evidence concerns the gene NPPB and pulmonary arterial hypertension.